^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

CYP17A1 inhibitor

7d
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer (clinicaltrials.gov)
P2, N=140, Recruiting, University of Nebraska | Not yet recruiting --> Recruiting
Enrollment open
|
abiraterone acetate • prednisone
8d
Extracellular vesicles derived from TNF-α-preconditioned mesenchymal stem cells mitigate inflammatory retinal injury. (PubMed, Extracell Vesicles Circ Nucl Acids)
In vivo, T-sEV treatment significantly preserved retinal a- and b-wave amplitudes and structural integrity... TNF-α preconditioning enhances MSC-derived sEV therapeutic capacity by enriching their anti-inflammatory miRNAs. T-sEV suppress pro-inflammatory macrophage activation and provide superior neuroprotection in a retinal degeneration model, indicating a safe and promising cell-free therapeutic strategy.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • ITGAM (Integrin, alpha M) • IL1R1 (Interleukin 1 receptor, type I) • CD86 (CD86 Molecule)
|
Akeega (abiraterone/niraparib)
8d
Synergistic piezo-immunotherapy enabled by lithium-doped SrTiO3 nanocatalysts for potent tumor ablation through ROS generation and immune activation. (PubMed, Regen Biomater)
As quantified by PFM, its surface potential and piezoelectric (butterfly-type) amplitude were ∼2.23-fold higher than those of the unmodified sample...The integration of piezocatalysis with immune activation resulted in a multimodal synergistic therapy that substantially improved overall antitumor efficacy. This work provides an innovative material-based strategy for enhancing tumor treatment through functional modulation and synergistic mechanisms.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8)
|
Akeega (abiraterone/niraparib)
10d
First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France. (PubMed, Drugs Real World Outcomes)
These are the first results describing the real-world use of olaparib in France in prostate cancer. Most patients included in the fEA had generally similar characteristics as the patients randomized in the PROpel clinical trial (NCT03732820) and initiated at the standard dose of 300 mg twice daily. No new safety signals were reported in this real-world patient population. The analyzed data did not modify the benefit-risk balance of olaparib.
Journal • Real-world evidence • PARP Biomarker
|
HRD (Homologous Recombination Deficiency)
|
Lynparza (olaparib) • abiraterone acetate • prednisone
13d
Preservation of Human Colonic Stem Cells Requires an ERK Dynamics Checkpoint Mediated by AKT. (PubMed, bioRxiv)
Stem cells must balance self-renewal and differentiation while remaining responsive to continuous mitogenic stimulation to preserve tissue homeostasis. When self-renewal is impaired, wound healing and barrier integrity decline, whereas loss of proper differentiation drives tumorigenesis. Our findings demonstrate that this balance in the human colon is achieved through temporal control of kinase signaling rather than modulation of ligand availability. By establishing an AKT-dependent ERK dynamics checkpoint, colonic stem cells suppress differentiation-inducing ERK pulses while maintaining growth factor responsiveness. These results identify kinase dynamics as a fundamental determinant of epithelial homeostasis and suggest that subtle alterations in these dynamics may destabilize tissue organization during regeneration or chronic inflammation. Temporal encoding of kinase activity thus represents a central organizing principle in human stem cell biology.
Journal
|
EGFR (Epidermal growth factor receptor)
|
Akeega (abiraterone/niraparib)
14d
Repeated Latency Prolongation of the Orbicularis Oris Muscle During Intraoperative Transcranial Facial Motor Evoked Potential Monitoring: A Case Report. (PubMed, Cureus)
In this rare case, we demonstrate reproducible Tc-fMEP latency prolongation suggestive of impaired neural conduction during vestibular schwannoma surgery. Latency prolongation of facial nerve motor evoked potentials, together with amplitude reduction, may represent a potential indicator of facial nerve functional impairment.
Journal
|
NF2 (Neurofibromin 2)
|
Akeega (abiraterone/niraparib)
14d
HARMONY: Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations (clinicaltrials.gov)
P2, N=0, Withdrawn, Qian Qin | Trial completion date: Apr 2028 --> Jan 2029 | Trial primary completion date: Apr 2027 --> Jan 2028
Trial completion date • Trial primary completion date
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD54L (DNA Repair And Recombination Protein RAD54)
|
docetaxel • abiraterone acetate • Akeega (abiraterone/niraparib)
14d
M25ABI: Comparison of standard abiraterone dosing and dosing based on abiraterone blood levels (2025-524440-35-00)
P4, N=230, Not yet recruiting, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
New P4 trial
|
abiraterone acetate
15d
Quaternary Ammonium Compound Induced Electrocardiogram Abnormalities with Body Fat as a Potential Effect Modifier: A Longitudinal Multiomics Panel Study in Elderly Adults. (PubMed, Environ Sci Technol)
Specifically, both BTMAC and DAD were associated with prolonged QRS time, whereas C8-DDAC was related to increased QT interval, QTc interval, and RV5/SV1 amplitude, as well as a reduced QRS time...Taken together, this study provides the first population-based evidence of QAC-associated cardiotoxicity and proposes the underlying biomolecular alternations. These insights offer a scientific foundation for developing targeted strategies to prevent and mitigate environmentally induced cardiovascular risks in susceptible populations.
Journal
|
NAP1L1 (Nucleosome Assembly Protein 1 Like 1) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
|
Akeega (abiraterone/niraparib)
15d
Dual suppression of stemness and redox adaptation in glioblastoma through filaggrin upregulation by an abiraterone-based HDAC inhibitor. (PubMed, J Biomed Sci)
This study establishes FLG as a novel therapeutic target in GBM and validates the suppressive efficacy of cp8 on the characteristics of TMZ resistance, highlighting the translational potential as a multitargeted therapy against TMZ-resistant GBM.
Journal
|
MGMT (6-O-methylguanine-DNA methyltransferase) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1) • FLG (Filaggrin)
|
temozolomide • abiraterone acetate • Zolinza (vorinostat)
21d
Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial). (PubMed, Prostate Cancer Prostatic Dis)
This study clarifies the clinical relevance of cytoplasmic AR-V7 in circulating tumor cells from men with metastatic castration-resistant prostate cancer. While nuclear-localized AR-V7 predicts extremely poor response, PFS, and overall survival with AR pathway inhibitors, cytoplasmic AR-V7 expands the definition of AR-V7-positive status and identifies patients with equally poor PFS and intermediate response and overall survival outcomes. Assessing both nuclear and cytoplasmic AR-V7 fractions may thus improve risk stratification heterogeneity and could better guide poor-risk ARPI treatment decisions by avoiding ineffective ARPI treatment, helping personalize therapy, and improving outcomes in men with mCRPC.
Journal
|
AR (Androgen receptor)
|
AR splice variant 7
|
CELLSEARCH®
|
Xtandi (enzalutamide) • abiraterone acetate
22d
Targeted inhibition of the CREB1-CtIP axis enhances the efficacy of abiraterone combined with radiotherapy in prostate cancer. (PubMed, Cell Death Dis)
Finally, our in vitro and in vivo experiments indicate that the CREB1 phosphorylation inhibitor 666-15 significantly enhances the therapeutic efficacy of Abi-RT combination therapy. In summary, our study reveals that inhibition of the CREB1-CtIP axis effectively improves the therapeutic outcomes of Abi-RT combination therapy, which may offer a novel clinical strategy for the treatment of prostate cancer.
Journal
|
HRD (Homologous Recombination Deficiency) • RBBP8 (RB Binding Protein 8, Endonuclease) • CREB1 (CAMP Responsive Element Binding Protein 1)
|
abiraterone acetate